Vol 7, No 3 (June 27, 2018): Chinese Clinical Oncology (Advances in Treatment and Care in Metastatic Breast Cancer)

Review Article

Advances in treatment and care in metastatic breast cancer (MBC): are there MBC patients who are curable?
Masaya Hattori, Hiroji Iwata
Resection of primary lesion for patients with metastatic breast cancer: where are we now?
Qiancheng Hu, Xiaorong Zhong, Xu Liu, Yuxin Xie, Kejia Hu, Ping He, Donghao Lu, Hong Zheng
Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer
Tomás Reinert, Bruno de Paula, Maryam Nemati Shafaee, Pedro Henrique Souza, Matthew J. Ellis, José Bines
Advances in chemotherapy for HER2-negative metastatic breast cancer
Hirofumi Mukai, Mayuko Ito
Advances in anti-HER2 therapy in metastatic breast cancer
Minya Yao, Peifen Fu
Immunotherapy for metastatic breast cancer
Tomoharu Sugie
Precision medicine in breast cancer
Yoichi Naito, Tetsuya Urasaki
Management of breast cancer brain metastases
Hideaki Takahashi, Mizuho Isogawa
Advances in treatment of metastatic breast cancer with bone metastasis
Ziping Wu, Jinsong Lu
Transitions in palliative care: conceptual diversification and the integration of palliative care into standard oncology care
Yudai Saga, Masanori Enokido, Yusei Iwata, Asao Ogawa
Advance care planning in metastatic breast cancer
Junji Matsuoka, Toshiki Kunitomi, Masahiko Nishizaki, Takayuki Iwamoto, Hideki Katayama

Disclosure:

The focused issue “Advances in Treatment and Care in Metastatic Breast Cancer” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Yutaka Yamamoto and Kazuo Tamura served as the unpaid Guest Editors for the focused issue.